Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program

References

• Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs. 2013;18(4):461–475.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–1493.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–1603.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–1614.
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–1982.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–1992.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–1135.
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014–1024.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–2428.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–2416.
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–1206.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705–716.
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207–1217.
   PubMed Web of Science ®Google Scholar
• Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015;22(11):861–870.
   PubMed Web of Science ®Google Scholar
• Lindor RA, Lindor KD. The value of observational research in liver diseases. Hepatology. 2011;53(1):1–3.
   PubMed Web of Science ®Google Scholar
• Chang TI, Winkelmayer WC. Comparative effectiveness research: what is it and why do we need it in nephrology? Nephrol Dial Transplant. 2012;27(6):2156–2161.
   PubMed Web of Science ®Google Scholar
• de Bruijn W, Ibanez C, Frisk P, et al. Introduction and utilization of high priced HCV medicines across Europe; implications for the future. Front Pharmacol. 2016;7:197.
   PubMed Web of Science ®Google Scholar
• O’Leary A Personal Communication. 2013.
   Google Scholar
• Garrison LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10(5):326–335.
   PubMed Web of Science ®Google Scholar
• Woods B, Faria R, Griffin S. Assessing the value of new treatments for hepatitis C: are international decision makers getting this right? Pharmacoeconomics. 2016;34(5):427–433.
   PubMed Web of Science ®Google Scholar
• Gray E, O’Leary A, Kieran JA, et al. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection. J Viral Hepat. 2016 Sep;23(9):677–686.
   PubMed Web of Science ®Google Scholar
• Gray E, O’Leary A, Stewart S, et al. High mortality during direct acting antiviral therapy for hepatitis C patients with child’s C cirrhosis: results from the Irish early access programme. J Hepatol. 2016;65(2):446–448.
   PubMed Web of Science ®Google Scholar
• Chung RT, Davis GL, Jensen DM et al. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954.
   PubMed Web of Science ®Google Scholar
• Pawlowsky JM, Aghemo A, Back D et al. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.
   PubMed Web of Science ®Google Scholar
• Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144(7):1450.e2–1455.e2.
   Web of Science ®Google Scholar
• Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology. 2015;61(1):41–45.
   PubMed Web of Science ®Google Scholar
• Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397–404.
   PubMed Web of Science ®Google Scholar
• Backus LI, Belperio PS, Shahoumian TA, et al. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther. 2016 Aug;44(4):400-410.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Gordon SC, et al. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care. 2016;22(6 Spec No.):Sp205–Sp211.
   PubMed Web of Science ®Google Scholar
• Curry MP, Bacon B, Flamm SL, et al. Effectiveness of 12 or 24 week ldv/sof and 12 week LDV/SOF + RBV in treatment-experienced patients with cirrhotic, genotype 1 hepatitis C: real-world experience from the Trio network. Hepatology. 2015;62:755A.
   Web of Science ®Google Scholar
• Foster GR, Irving WL, Cheung MC, et al. Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224–1231.
   PubMed Web of Science ®Google Scholar
• Kieran J, Mushtaq H, Bergin C, et al. Demographics and health-state utilities of Irish patients with hepatitis C infection; use of the 5-level EQ-5D questionnaire. Value Health. 2012;15(7):A528.
   Web of Science ®Google Scholar
• Iyengar S, Tay-Teo K, Vogler S, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032.
   PubMed Web of Science ®Google Scholar
• Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
   PubMed Web of Science ®Google Scholar
• Faria R, Woods B, Griffin S, et al. Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. Aliment Pharmacol Ther. 2016;44(8):866–876.
   PubMed Web of Science ®Google Scholar
• NICE. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C. London: NICE; 2015. Report.
   Google Scholar
• NICE. Sofosbuvir for treating chronic hepatitis C. London: NICE; 2015. Report.
   Google Scholar
• NICE. Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C infection. London: NICE; 2015. Report.
   Google Scholar
• NICE. Daclatasvir for treating chronic hepatitis C. London: NICE; 2015. Report.
   Google Scholar
• NICE. Ledipasvir-sofosbuvir for treating chronic hepatitis C. London: NICE; 2015. Report.
   Google Scholar
• Younossi ZM, Singer ME, Mir HM, et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2014;60(3):530–537.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162(6):397–406.
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Schwarzinger M, Obach D, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol. 2014;61(1):7–14.
   PubMed Web of Science ®Google Scholar
• San Miguel R, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut. 2015;64(8):1277–1288.
   PubMed Web of Science ®Google Scholar
• Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat. 2015;22(4):376–383.
   PubMed Web of Science ®Google Scholar
• Bennett H, Gordon J, Jones B, et al. Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. Eur J Health Econ. 2016 Nov 1. [Epub ahead of print].
   PubMedGoogle Scholar
• Martin NK, Vickerman P, Dore GJ, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol. 2016;65(1):17–25.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–733.
   PubMed Web of Science ®Google Scholar
• Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719–726.
   PubMed Web of Science ®Google Scholar
• ANRS. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65(4):734–740.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65(4):741–747.
   PubMed Web of Science ®Google Scholar